What to Do After a First Rejection on an Oral Blood Cancer Drug

What did the new study find about oral blood cancer prescriptions?

A 2026 Journal of Clinical Oncology study found that initial rejections of specialty oral anticancer prescriptions for blood cancers were common, especially for commercially insured patients. Prior authorization and formulary restrictions were frequent rejection reasons. Many prior authorization rejections were later approved within 90 days. The study, led by Jalpa A. Doshi and colleagues, followed new specialty oral anticancer prescriptions for blood cancers written in 2022 in a nationwide sample of Medicare and commercially insured patients. The researchers tracked each prescription from the first claim through insurer approval or rejection and through whether an approved prescription was filled (Doshi et al., J Clin Oncol, DOI 10.1200/ JCO-26-00247; Penn Medicine news summary, Sept 30, 2026). Insurers initially rejected 84.0% of commercial prescriptions and 64.9% of Medicare prescriptions. Among prescriptions initially rejected for prior authorization, 71.3% of commercial rejections and 85.9% of Medicare rejections were later approved within 90 days. Ultimately, 45.5% of commercial patients and 54.5% of Medicare patients both received approval and filled the prescription. Fill rates for approved prescriptions dropped sharply when out-of-pocket costs exceeded $175 (Doshi et al., JCO; Penn Medicine; Healio coverage, Oct 21, 2026). The authors describe access breaking at two points: insurer rejection before approval, and out-of-pocket cost after approval. The prescriptions studied are from 2022, before Medicare's Part D annual out-of-pocket cap ($2,100 in 2026), so the cost findings predate that cap (Medicare.gov, Part D costs; CMS CY 2026 Part D Redesign). For the broader specialty-access pattern, see specialty drug access denials. For how often appeals change outcomes after a first no, see the appeal gap.

If your first submission was rejected, what should you do next?

A first rejection means the plan has not approved coverage yet. The JCO analysis found that a large share of prior authorization rejections were later approved within 90 days (Doshi et al., JCO; Healio).

Read the rejection reason. Prior authorization missing, not on formulary, quantity limit, and administrative errors are different problems with different paperwork. Start with how to read a denial letter. If the notice looks like an EOB-style document, also see how to read a denied EOB.

Call your prescriber's office the same day. Ask them to submit or complete the prior authorization, or to request a formulary exception if the drug is non-preferred or excluded.

Ask how long the plan says a decision should take, and whether an expedited review is available if a delay would put your health at risk under the plan's own rules.

Keep a paper trail. Save the rejection, the date, any reference numbers, and every fax or portal confirmation.

If the plan still says no, use the appeal path on the denial letter. Deadlines are on the letter (insurance appeal deadline clock). If you miss the appeal deadline on the letter, the plan can refuse to review that appeal. See how to appeal.

What if the drug is approved but you still cannot afford to fill it?

The same study found that approval alone did not guarantee a fill. As patients' out-of-pocket share climbed, fill rates dropped (Doshi et al., JCO; Penn Medicine; Healio). More on that barrier is in approved but can't afford. Ask your care team or a financial navigator about manufacturer assistance, foundation help, and, if you have Medicare drug coverage, whether spreading costs through Medicare's prescription payment plan is an option for you. Confirm eligibility rules for your insurance type before you rely on any program.

How can Ellen® help after an oral blood cancer drug rejection?

Upload the rejection or denial letter to EllenRx®'s Denial Decoder to see what reason the plan gave and what paperwork usually comes next. If you need to build an appeal or exception packet, continue in the Appeal wizard. If the medication is approved and the barrier is cost, open Ellen's Financial Assistance finder for programs that may apply. You can also start from I Was Denied. Your next step: upload the notice to the Denial Decoder, then work with your prescriber on the prior authorization or exception before the deadline on your notice.

Sources

Doshi JA, Li P, Geng Z, et al. Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients. Journal of Clinical Oncology. 2026. DOI 10.1200/JCO-26-00247

Penn Medicine news release summarizing the study, Sept 30, 2026

Mark Leiser, Healio, coverage of insurance barriers and out-of-pocket costs limiting access to blood cancer drugs, Oct 21, 2026

Medicare.gov, Part D costs (2026 out-of-pocket threshold $2,100)

CMS, Final CY 2026 Part D Redesign Program Instructions